Drugs / Darbepoetin alpha
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT00557817 Comparator | Mar 2004 → Aug 2008 | hematopoietic and lymphoid cell neoplasm | University of Liege | Completed | No outcome recorded |
| Phase 3 | NCT01196715 Comparator | Nov 2010 → Oct 2015 | myelodysplastic syndrome | Barts & The London NHS Trust | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darbepoetin alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00557817 ↗ |
| Route | Subcutaneous | “administered subcutaneously (s.c.)” NCT00557817 ↗ |